|
Published by: Decision Resources
Published: Dec. 16, 2008 - 33 Pages
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Overview of Sjögren’s Syndrome
- Disease Description and Etiology
- Diagnosis
- Clinical Manifestations
- Dry Mouth
- Dry Eye
- Other Symptoms
- Epidemiology
- Overview
- Methods
- Current Therapies for Sjögren’s Syndrome
- Current Treatments for Dry Eye in Sjögren’s Syndrome
- Allergan/Inspire Pharmaceutical’s Restasis
- Punctal-Plug Treatments
- Current Treatments for Dry Mouth in Sjögren’s Syndrome
- Eisai/Kissei Pharmaceutical’s Salagen
- Daiichi Sankyo’s Evoxac
- Current Treatments for Systemic Symptoms of Sjögren’s Syndrome
- Hydroxychloroquine
- Methotrexate
- Azathioprine
- Emerging Therapies for Sjögren’s Syndrome
- Systemic Treatments for Sjögren’s Syndrome
- Rituxan/MabThera (rituximab)
- Epratuzumab
- Remicade (infl iximab)
- Enbrel (etanercept)
- Other TNF-α Inhibitors
- Emerging Therapies for Dry Eyes in Sjögren’s Syndrome
- Prolacria (diquafosol tetrasodium; ophthalmic solution)
- Ecabet Sodium (ophthalmic solution)
- Rebamipide (ophthalmic suspension)
- Emerging Therapies for Dry Mouth in Sjögren’s Syndrome
- NGX-267
- Outlook for the Sjögren’s Syndrome Market
- Appendix A: Bibliography
- Tables
- 1. Comparison of Diagnostic Criteria for Sjögren’s Syndrome
- 2. Current Therapies for Sjögren’s Syndrome
- 3. Emerging Therapies for Sjögren’s Syndrome, 2008
- Figures:
- 1. Rheumatologists’ Estimate of the Prevalence of Sjögren’s Syndrome Symptoms
- 2. Prevalent Cases of Sjögren’s Syndrome, 2007-2017
- 3. Survey Question: Please indicate your fi rst-, second-, and third-line therapy for the treatment of Sjögren’s syndrome-associated dry eye
- 4. Survey Question: Please indicate your fi rst-, second-, and third-line therapy for the systemic treatment of Sjögren’s syndrome
- 5. Survey Question: If Rituxan’s effi cacy in treating Sjögren’s syndrome can be established, will you prescribe Rituxan to your patients?
- 6. Survey Question: What agents do you believe are most likely to be replaced by Rituxan?
- 7. Survey Question: If epratuzumab’s effi cacy in treating Sjögren’s syndrome can be established, will you prescribe epratuzumab to your patients?
- 8. Survey Question: What agents do you believe are most likely to be replaced by epratuzumab?
- 9. Survey Question: If Remicade’s effi cacy in treating Sjögren’s syndrome can be established, will you prescribe Remicade to your patients
- 10. Survey Question: If Prolacria’s effi cacy in treating Sjögren’s syndrome can be established, will you prescribe Prolacria to your patients
- 11. Survey Question: What agents do you believe are most likely to be replaced by Prolacria?
- 12. Survey Question: If ecabet sodium’s effi cacy in treating Sjögren’s syndrome can be established, will you prescribe ecabet sodium to your patients
- 13. Survey Question: If NGX-267’s effi cacy in treating Sjögren’s syndrome can be established, will you prescribe NGX-267 to your patients
AbstractSjögren’s syndrome (SS) is one of the most common autoimmune diseases, affecting more than 1 million
individuals in the United States. Although the majority of cases are relatively benign, in more-severe
cases, patients can develop life-threatening symptoms and complications, including renal or liver
failure and B-cell lymphoma.
At this time SS has no cure, and treatment is focused primarily on the alleviation of symptoms and the
prevention of long-term organ damage. Because SS affects multiple organs within the body, polypharmacy
is common, with rheumatologists surveyed by Decision Resources estimating that more than
90% of their SS patients receive more than one treatment. The development of a single agent that addresses
multiple symptoms of the disease is a considerable unmet need in SS treatment.
This report provides an overview of SS, including the disease’s etiology, diagnosis, and symptoms.
Decision Resources surveyed U.S. rheumatologists to determine their prescribing preferences for SS;
we present the most commonly prescribed prescription agents used to treat the disease. The prevalence
of SS is high compared with that of many other infl ammatory diseases, and we discuss the current
SS prevalence and our forecast for patient population growth over the next ten years. Perhaps owing
to this high patient population, signifi cant development is ongoing for SS, and we discuss late-stage
emerging agents. Finally, we present our outlook for the SS market.
Get Full Details About This Report >>
|
